A dose titration protocol for once-daily insulin glargine 300 U/mL for the treatment of diabetes mellitus in dogs.

IGla300 is an effective once-daily insulin therapy for canine diabetes mellitus.

This study evaluated a dose titration protocol for once-daily insulin glargine 300 U/mL (IGla300) in dogs with diabetes mellitus. IGla300 is characterized by a prolonged duration of action, a peakless time-action profile, and low potency, making it suitable for use as a basal insulin. The study aimed to determine the efficacy and safety of IGla300 in managing canine diabetes. The researchers conducted a clinical trial involving purpose-bred dogs diagnosed with diabetes mellitus. The dogs were administered once-daily doses of IGla300, and their blood glucose levels were monitored over a specified period. The results demonstrated that IGla300 effectively controlled blood glucose levels in the majority of the dogs, with minimal adverse effects observed. The study concluded that IGla300 is a viable option for once-daily insulin therapy in dogs with diabetes mellitus, offering a practical and effective treatment alternative.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.